Funding Opportunities for Innovative Clinical and Translational Science at UAMS

The overall goal of the TRI is to transform the pace, effectiveness, and quality of translational research among UAMS and its partners, resulting in better health for all Arkansans. The TRI funding programs intend to 1) facilitate research innovation and progress, 2) stimulate and solidify research collaborations and 3) promote high-quality translational research. Awards are intended to support novel research studies; these awards will not support projects that are minor offshoots of ongoing research or provide bridge funding to investigators.

The awards encourage investigators to develop research programs that successfully compete for extramural funding. The TRI will support investigators by providing guidance, resources, and feedback. Please see below for the available funding mechanisms and full RFAs.

Visit our FAQ page for answers to commonly asked questions about the TRI Pilot Studies program.

RFAs Available 

The TRI is currently offering the following award mechanisms:

• Annual TRI Pilot Research Awards in Clinical and Translational Science ($50,000, one year of funding)
  
  Instructions for the Pre-proposal
  Deadline: April 6, 2012
  
  Instructions for the Full Application (Invited Applications only)
  Deadline: May 31, 2012
  

• Targeted Awards For Innovative Clinical and Translational Research - Focus: Drug and Biologics Development (1-3 awards, 200,000 total available).
  
  Instructions for Applicants
  Deadline: March 21, 2012
  

Grant Forms

These forms are to be filled out, saved, and submitted along with invited grant proposals.

Application Cover Sheet

Biosketch Form

Other Support Form

Detailed Budget Form

Budget Justification Form

Milestones and Evaluation Table (Word .doc)

INNOVATIVE CLINICAL AND TRANSLATIONAL RESEARCH AWARD

The UAMS Translational Research Institute (TRI) invites applications for TRI Drug and Biologics Development (DBD) Awards. The TRI expects to fund 1-3 DBD Awards up to a total of $200,000 and will provide one year of funding. Fundable projects and their budgets may vary significantly, depending on the needs of the applicant. Examples may include smaller projects requesting licensing/legal support to move projects toward FDA approval and Phase I trials, support to complete key toxicological or teratological studies to file INDs with the FDA, or larger studies supporting key trials in humans that will significantly and quickly advance the PI's work. Early stage drug and biologics development, such as screening to select new medications, will not be considered.